Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

indium In 111-DOTA-basiliximab

A radioimmunoconjugate composed of basiliximab, a chimeric, mouse-human monoclonal antibody directed against the alpha subunit of interleukin-2 receptor (IL-2R alpha, CD25 or Tac antigen), and conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and labeled with the radioisotope indium In 111, with potential use as an imaging agent. Upon administration of indium In 111-DOTA- basiliximab, the basiliximab moiety targets and binds to IL-2R alpha expressed on the surface of activated T lymphocytes. Upon binding and gamma scintigraphy, IL-2R alpha-expressing T cells can be visualized and the binding and biodistribution of basiliximab can be assessed.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:111In-DOTA-basiliximab
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search